IRLAB publishes preclinical data on mesdopetam in the esteemed European Journal of Neuroscience

Gothenburg, March 12, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that preclinical data on mesdopetam has been published in the prestigious, peer-reviewed medical journal European Journal of Neuroscience, EJN. The data provide new insights into the system-level mechanisms behind the antidyskinetic effect of mesdopetam and suggest potential additional benefits in the treatment of Parkinson’s related psychosis.

IRLAB participates in Stora Aktiedagarna

IRLAB reports topline results from a Phase IIb study of pirepemat in patients with Parkinson’s disease